← Russell 3000 cross-section

LH LABCORP HOLDINGS INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$27.5bn
Revenue TTM
$14.3bn
Net income TTM
$1.0bn
Free cash flow
$1.2bn
Composite score
53.3
Sector rank
#358

Valuation

P / E
27.4
EV / EBITDA
15.1
EV / sales
2.3
FCF yield
4.20%
Earnings yield vs 10-yr
-1.08pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
7.0%
EBITDA margin
15.3%
ROE
11.7%
ROIC
10.4%
Revenue growth
6.4%

Insider activity, last 90 days

Net open-market
$-3.47m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

GENERAL (dollars in millions) For the three months ended June 30, 2026, the Company’s revenues were $3,731.1, an increase of 5.8% from $3,527.3 for the corresponding period in 2025. The 5.8% increase for the three months ended June 30, 2026, as compared to the corresponding period in 2025, was primarily due to organic revenue of 4.2%, acquisitions, net of divestitures, of 1.2%, and favorable foreign currency translation of 0.4%. For the six months ended June 30, 2026, the Company’s revenues were $7,268.7, an increase of 5.8% from $6,872.4 for the corresponding period in 2025. …LABCORP HOLDINGS INC., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →